Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent

Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly resulted in a global pandemic with approximately 4 million deaths. Effective oral antiviral agents are urgently needed to treat coronavirus disease-2019 (COVID-19), block SARS-CoV-2 transmission, and preven...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ching-Chi Lee, Chih-Chia Hsieh, Wen-Chien Ko
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	COVID-19 antiviral agents molnupiravir RNA polymerase inhibitor clinical trial Therapeutics. Pharmacology RM1-950
Acceso en línea:	https://doaj.org/article/74981b2833ae44b6bb4f9ec78331bb5d
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:74981b2833ae44b6bb4f9ec78331bb5d
record_format	dspace
spelling	oai:doaj.org-article:74981b2833ae44b6bb4f9ec78331bb5d2021-11-25T16:22:13ZMolnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent10.3390/antibiotics101112942079-6382https://doaj.org/article/74981b2833ae44b6bb4f9ec78331bb5d2021-10-01T00:00:00Zhttps://www.mdpi.com/2079-6382/10/11/1294https://doaj.org/toc/2079-6382Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly resulted in a global pandemic with approximately 4 million deaths. Effective oral antiviral agents are urgently needed to treat coronavirus disease-2019 (COVID-19), block SARS-CoV-2 transmission, and prevent progression to severe illness. Molnupiravir (formerly EIDD-2801), a prodrug of beta-<span style="font-variant: small-caps;">d</span>-N4-hydroxycytidine (EIDD-1931) and an inhibitor of RNA-dependent RNA polymerase, possesses significant activity against SARS-CoV-2. Its prophylactic efficacy has been evidenced in a ferret model. Two phase-I trials (NCT04392219 and NCT04746183) have demonstrated that oral molnupiravir is safe and well-tolerated at therapeutic doses. After five-days of oral molnupiravir therapy, satisfactory efficacies, assessed by eliminating nasopharyngeal virus in patients with early and mild COVID-19, were disclosed in two phase-II trials (NCT04405739 and NCT 04405570). Two phase-II/III trials, NCT04575597 and NCT04575584, with estimated enrollments of 1850 and 304 cases, respectively, are ongoing. The NCT04575597 recently released that molnupiravir significantly reduced the risk of hospitalization or death in adults experiencing mild or moderate COVID-19. To benefit individual and public health, clinical applications of molnupiravir to promptly treat COVID-19 patients and prevent SARS-CoV-2 transmission may be expected.Ching-Chi LeeChih-Chia HsiehWen-Chien KoMDPI AGarticleCOVID-19antiviral agentsmolnupiravirRNA polymerase inhibitorclinical trialTherapeutics. PharmacologyRM1-950ENAntibiotics, Vol 10, Iss 1294, p 1294 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	COVID-19 antiviral agents molnupiravir RNA polymerase inhibitor clinical trial Therapeutics. Pharmacology RM1-950
spellingShingle	COVID-19 antiviral agents molnupiravir RNA polymerase inhibitor clinical trial Therapeutics. Pharmacology RM1-950 Ching-Chi Lee Chih-Chia Hsieh Wen-Chien Ko Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent
description	Since December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has rapidly resulted in a global pandemic with approximately 4 million deaths. Effective oral antiviral agents are urgently needed to treat coronavirus disease-2019 (COVID-19), block SARS-CoV-2 transmission, and prevent progression to severe illness. Molnupiravir (formerly EIDD-2801), a prodrug of beta-<span style="font-variant: small-caps;">d</span>-N4-hydroxycytidine (EIDD-1931) and an inhibitor of RNA-dependent RNA polymerase, possesses significant activity against SARS-CoV-2. Its prophylactic efficacy has been evidenced in a ferret model. Two phase-I trials (NCT04392219 and NCT04746183) have demonstrated that oral molnupiravir is safe and well-tolerated at therapeutic doses. After five-days of oral molnupiravir therapy, satisfactory efficacies, assessed by eliminating nasopharyngeal virus in patients with early and mild COVID-19, were disclosed in two phase-II trials (NCT04405739 and NCT 04405570). Two phase-II/III trials, NCT04575597 and NCT04575584, with estimated enrollments of 1850 and 304 cases, respectively, are ongoing. The NCT04575597 recently released that molnupiravir significantly reduced the risk of hospitalization or death in adults experiencing mild or moderate COVID-19. To benefit individual and public health, clinical applications of molnupiravir to promptly treat COVID-19 patients and prevent SARS-CoV-2 transmission may be expected.
format	article
author	Ching-Chi Lee Chih-Chia Hsieh Wen-Chien Ko
author_facet	Ching-Chi Lee Chih-Chia Hsieh Wen-Chien Ko
author_sort	Ching-Chi Lee
title	Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent
title_short	Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent
title_full	Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent
title_fullStr	Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent
title_full_unstemmed	Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent
title_sort	molnupiravir—a novel oral anti-sars-cov-2 agent
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/74981b2833ae44b6bb4f9ec78331bb5d
work_keys_str_mv	AT chingchilee molnupiraviranoveloralantisarscov2agent AT chihchiahsieh molnupiraviranoveloralantisarscov2agent AT wenchienko molnupiraviranoveloralantisarscov2agent
_version_	1718413207151837184

Molnupiravir—A Novel Oral Anti-SARS-CoV-2 Agent

Ejemplares similares